DBV Technologies Raises $30 Million Through Nasdaq ATM Program

DBV Technologies, a clinical-stage biopharmaceutical company, has announced the sale of approximately $30 million of American Depositary Shares (ADSs) through its At-The-Market (ATM) program on Nasdaq. The agreement was made on October 6, 2025, as part of the company's efforts to enhance its capital resources.

The 2,307,692 ADSs, representing 11,538,460 ordinary shares, were sold at an at-the-market price of $13.00 per ADS. This issuance results in a dilution of approximately 7.77% of the company's existing shares. The new shares are expected to trade on Nasdaq and Euronext Paris starting October 8, 2025.

Invus, through Citizens Capital Markets acting as the sales agent, acquired these shares under favorable market conditions. The company's strategic move did not require approval from the French Financial Markets Authority due to specific exemptions under the EU Prospectus Regulation.